Clinical Efficacy First
Clinical efficacy will be the key parameter to be considered when preparing lists of drugs, including the vital and essential drug list (VEDL)
That was the comment given by Elena Maximkina, Head of Department of Drug Provision at the Ministry of Healthcare of the Russian Federation at the recent Gaydar Forum, held at the Russian Presidential Academy of National Economy and Public Administration on January 12-14.
She stressed, that today the cost of the drug is particularly important for the Ministry of Healthcare, but still efficacy is much more important.
This opinion was supported by Evgeniy Shlyakhto, RAS Academician, General Director of North-Western Federal medical Research Center named after V.A. Almazov. He remarked, that current turn towards value-based patient-focused medicine will help decrease the rate of repeated hospitalizations, improve the patient’s quality of life and lead to cost saving in the field of healthcare.
Vadim Vlasov, President of Novartis Russia commented on the need to correlate budget and pricing to the treatment effects. He stressed, that in the near future focus should be made on value-based medicine, when payment is made only after the effects of treatment are confirmed. Naturally, the effectiveness of drugs will have to be confirmed, for that purpose a dedicated institute needs to be established, as well as platforms that would provide such an opportunity. But this work needs to be done. Novartis has already made an offer to the Ministry of Healthcare on certain therapeutic areas, and a pilot project is being planned.